Prevention of cardiotoxicity among survivors of childhood cancer

Kelley K. Hutchins, Hani Siddeek, Vivian I. Franco, Steven E Lipshultz

Research output: Contribution to journalArticle

17 Scopus citations


The number of survivors of childhood cancers has increased exponentially over the past few decades. However, these survivors are also at substantially increased long-term risk of morbidity and mortality, especially from treatment-related cardiotoxicity. Preventing these risks is now a priority when treating children and adolescents with cancer. Dexrazoxane reduces the risk of anthracycline-induced cardiotoxicity among adults and children with cancer without reducing its antineoplastic effects or event-free survival. Thus, it should be strongly considered as a part of therapy for children and adolescents treated with anthracyclines.

Original languageEnglish (US)
JournalBritish Journal of Clinical Pharmacology
StateAccepted/In press - 2016
Externally publishedYes


  • Cardiotoxicity
  • Childhood cancer
  • Dexrazoxane
  • Survivor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Prevention of cardiotoxicity among survivors of childhood cancer'. Together they form a unique fingerprint.

  • Cite this